Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System
MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) ... Read More
Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System
Boston Scientific Corporation (NYSE:BSX) is one of Goldman Sachs’ top healthcare stock picks. On July 7, Boston Scientific (NYSE:BSX) saw its shares rise as TD Cowen reaffirmed its Buy rating and $115 ... Read More
Boston Scientific expands Farapulse’s reach in afib with new FDA approval
Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use into patients with persistent atrial fibrillation lasting at least seven ... Read More
CMS adds reimbursement for cardiac ablation in ASCs
The Centers for Medicare and Medicaid Services (CMS) has provided a major reimbursement update for cardiac ablation technologies. Read More
Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ... Read More
Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus